Future DTC drug ads will be hyper-targeted

04/2/2012 | Medical Marketing & Media

As big pharma's focus shifts from creating blockbusters to developing biologic drugs and other niche products, drug marketing will become more narrow, targeted and multifaceted, writes Matthew Arnold. For example, AbelsonTaylor's campaign for Pfizer and Amgen's Enbrel features a celebrity spokesman, but a separate campaign for the therapy targets patients with plaque psoriasis. New measurement and analysis tools, as well as consumer channels, allow marketers to reach potential patients with more precision, experts say.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA